NCT04774068View on ClinicalTrials.gov

Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

October 27, 2024

Study Completion Date

October 27, 2024

Conditions

Recurrent Anaplastic Large Cell LymphomaRecurrent Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Transformed Mycosis FungoidesRefractory Anaplastic Large Cell LymphomaRefractory Mature T-Cell and NK-Cell Non-Hodgkin LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaRefractory Transformed Mycosis FungoidesT-Cell Non-Hodgkin Lymphoma

Interventions

DRUG

Parsaclisib

Given PO

DRUG

Romidepsin

Given IV

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors

lead

Walter Hanel

OTHER

NCT04774068 - Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas | Biotech Hunter | Biotech Hunter